How AI helped researchers track recovery from depression

AdobeResearcherssaythey’vebeenabletomeasurerecoveryfromtreatment-resistantdepressionthroughbrainscan MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending




focus

author：knowledge    Page View：23495
In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
Scott Olson/Getty Images

WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

advertisement

The negotiated prices won’t take effect until 2026. 

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Changes to biosimilar regulatory framework must prioritize patients
Next article： Drug repurposing or repositioning? The language matters